- $521.22m
- $286.53m
- $83.33m
- 52
- 16
- 63
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.01 | ||
| Price to Tang. Book | 2.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -64.32% | ||
| Return on Equity | -79.49% | ||
| Operating Margin | -280.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 154.57 | 470.35 | 112.72 | 90.24 | 83.33 | 314.64 | 292.99 | 18.79% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Directors
- Allan Fox CHM (72)
- Kenneth Mills PRE (46)
- Vittal Vasista CFO (53)
- Curran Simpson COO (59)
- Olivier Danos SVP (63)
- Patrick Christmas SVP (50)
- Steve Pakola SVP (52)
- A. N. Karabelas LED (68)
- Jean Bennett DRC
- George Migausky DRC (66)
- Daniel Abdun-Nabi IND (66)
- Alexandra Glucksmann IND (62)
- David Stump IND (71)
- Daniel Tasse IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 16th, 2008
- Public Since
- September 17th, 2015
- No. of Shareholders
- 5
- No. of Employees
- 353
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 50,116,910
- Address
- 9804 Medical Center Drive, ROCKVILLE, 20850
- Web
- https://regenxbio.com/
- Phone
- +1 2405528181
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for RGNX
Q1 2025 Regenxbio Inc Earnings Call
Regenxbio Inc Annual Shareholders Meeting
Regenxbio Inc Annual Shareholders Meeting
Q2 2025 Regenxbio Inc Earnings Release
Q3 2025 Regenxbio Inc Earnings Release
Similar to RGNX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Regenxbio share price?
As of Today at 22:54 UTC, shares in Regenxbio are trading at $10.40. This share price information is delayed by 15 minutes.
How has the Regenxbio share price performed this year?
Shares in Regenxbio last closed at $10.40 and the price had moved by -37.5% over the past 365 days. In terms of relative price strength the Regenxbio share price has underperformed the S&P500 Index by -43.64% over the past year.
What are the analyst and broker recommendations for Regenxbio?
The overall consensus recommendation for Regenxbio is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Regenxbio dividend yield?
Regenxbio does not currently pay a dividend.
Does Regenxbio pay a dividend?
Regenxbio does not currently pay a dividend.
When does Regenxbio next pay dividends?
Regenxbio does not currently pay a dividend.
How do I buy Regenxbio shares?
To buy shares in Regenxbio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Regenxbio?
As of the previous close price of $10.40, shares in Regenxbio had a market capitalisation of $521.22m.
Where are Regenxbio shares listed?
Here are the trading details for Regenxbio:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: RGNX
What kind of share is Regenxbio?
Based on an overall assessment of its quality, value and momentum Regenxbio is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Regenxbio share price forecast for 2025?
The analyst consensus target price for shares in Regenxbio is $32.92. That is 216.54% above the last closing price of $10.40.
Analysts covering Regenxbio currently have a consensus Earnings Per Share (EPS) forecast of -$0.49 for the next financial year.
Find out moreWhat is the trend in the Regenxbio share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Regenxbio. Over the past six months, its share price has outperformed the S&P500 Index by +18.86%.
As of the last closing price of $10.40, shares in Regenxbio were trading +11.21% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Regenxbio PE Ratio?
The Regenxbio PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Regenxbio?
Regenxbio's management team is headed by:
- Allan Fox - CHM
- Kenneth Mills - PRE
- Vittal Vasista - CFO
- Curran Simpson - COO
- Olivier Danos - SVP
- Patrick Christmas - SVP
- Steve Pakola - SVP
- A. N. Karabelas - LED
- Jean Bennett - DRC
- George Migausky - DRC
- Daniel Abdun-Nabi - IND
- Alexandra Glucksmann - IND
- David Stump - IND
- Daniel Tasse - IND